These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 38598969)
1. Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN. Reijman MD; Kusters DM; Groothoff JW; Arbeiter K; Dann EJ; de Boer LM; de Ferranti SD; Gallo A; Greber-Platzer S; Hartz J; Hudgins LC; Ibarretxe D; Kayikcioglu M; Klingel R; Kolovou GD; Oh J; Planken RN; Stefanutti C; Taylan C; Wiegman A; Schmitt CP Atherosclerosis; 2024 May; 392():117525. PubMed ID: 38598969 [TBL] [Abstract][Full Text] [Related]
2. Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia: an expert consensus statement from ERKNet and ESPN. Reijman MD; Kusters DM; Groothoff JW; Arbeiter K; Dann EJ; de Boer LM; de Ferranti SD; Gallo A; Greber-Platzer S; Hartz J; Hudgins LC; Ibarretxe D; Kayikcioglu M; Klingel R; Kolovou GD; Oh J; Planken RN; Stefanutti C; Taylan C; Wiegman A; Schmitt CP medRxiv; 2023 Nov; ():. PubMed ID: 38014132 [TBL] [Abstract][Full Text] [Related]
3. Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries. Reijman MD; Tromp TR; Hutten BA; Hovingh GK; Blom DJ; Catapano AL; Cuchel M; Dann EJ; Gallo A; Hudgins LC; Raal FJ; Ray KK; Sadiq F; Soran H; Groothoff JW; Wiegman A; Kusters DM; ; Lancet Child Adolesc Health; 2024 Jul; 8(7):491-499. PubMed ID: 38759658 [TBL] [Abstract][Full Text] [Related]
4. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial. Stefanutti C; Blom DJ; Averna MR; Meagher EA; Theron Hd; Marais AD; Hegele RA; Sirtori CR; Shah PK; Gaudet D; Vigna GB; Sachais BS; Di Giacomo S; du Plessis AM; Bloedon LT; Balser J; Rader DJ; Cuchel M; Atherosclerosis; 2015 Jun; 240(2):408-14. PubMed ID: 25897792 [TBL] [Abstract][Full Text] [Related]
5. Treatment of homozygous familial hypercholesterolaemia in paediatric patients: A monocentric experience. Buonuomo PS; Macchiaiolo M; Leone G; Valente P; Mastrogiorgio G; Gnazzo M; Rana I; Gonfiantini MV; Gagliardi MG; Romano F; Bartuli A Eur J Prev Cardiol; 2018 Jul; 25(10):1098-1105. PubMed ID: 29785886 [TBL] [Abstract][Full Text] [Related]
6. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia. Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880 [TBL] [Abstract][Full Text] [Related]
7. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Cuchel M; Bruckert E; Ginsberg HN; Raal FJ; Santos RD; Hegele RA; Kuivenhoven JA; Nordestgaard BG; Descamps OS; Steinhagen-Thiessen E; Tybjærg-Hansen A; Watts GF; Averna M; Boileau C; Borén J; Catapano AL; Defesche JC; Hovingh GK; Humphries SE; Kovanen PT; Masana L; Pajukanta P; Parhofer KG; Ray KK; Stalenhoef AF; Stroes E; Taskinen MR; Wiegman A; Wiklund O; Chapman MJ; Eur Heart J; 2014 Aug; 35(32):2146-57. PubMed ID: 25053660 [TBL] [Abstract][Full Text] [Related]
8. Current Role of Lipoprotein Apheresis. Thompson G; Parhofer KG Curr Atheroscler Rep; 2019 May; 21(7):26. PubMed ID: 31041550 [TBL] [Abstract][Full Text] [Related]
9. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. France M; Rees A; Datta D; Thompson G; Capps N; Ferns G; Ramaswami U; Seed M; Neely D; Cramb R; Shoulders C; Barbir M; Pottle A; Eatough R; Martin S; Bayly G; Simpson B; Halcox J; Edwards R; Main L; Payne J; Soran H; Atherosclerosis; 2016 Dec; 255():128-139. PubMed ID: 27839699 [TBL] [Abstract][Full Text] [Related]
10. Analysis of circulating miRNAs in patients with familial hypercholesterolaemia treated by LDL/Lp(a) apheresis. Dlouha D; Blaha M; Blaha V; Fatorova I; Hubacek JA; Stavek P; Lanska V; Parikova A; Pitha J Atheroscler Suppl; 2017 Nov; 30():128-134. PubMed ID: 29096828 [TBL] [Abstract][Full Text] [Related]
11. Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989-2017. Pottle A; Thompson G; Barbir M; Bayly G; Cegla J; Cramb R; Dawson T; Eatough R; Kale V; Neuwirth C; Nicholson K; Payne J; Scott J; Soran H; Walji S; Watkins S; Weedon H; Nath Datta DB Atherosclerosis; 2019 Nov; 290():44-51. PubMed ID: 31563836 [TBL] [Abstract][Full Text] [Related]
12. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study). Waldmann E; Vogt A; Crispin A; Altenhofer J; Riks I; Parhofer KG Atherosclerosis; 2017 Apr; 259():20-25. PubMed ID: 28279833 [TBL] [Abstract][Full Text] [Related]
13. The Low-Density Lipoprotein Receptor Genotype Is a Significant Determinant of the Rebound in Low-Density Lipoprotein Cholesterol Concentration After Lipoprotein Apheresis Among Patients With Homozygous Familial Hypercholesterolemia. Drouin-Chartier JP; Tremblay AJ; Bergeron J; Lamarche B; Couture P Circulation; 2017 Aug; 136(9):880-882. PubMed ID: 28847800 [No Abstract] [Full Text] [Related]
14. Pregnancy in homozygous familial hypercholesterolemia--Importance of LDL-apheresis. Blaha M; Lanska M; Blaha V; Boudys L; Zak P Atheroscler Suppl; 2015 May; 18():134-9. PubMed ID: 25936317 [TBL] [Abstract][Full Text] [Related]
15. High serum triglyceride concentrations in patients with homozygous familial hypercholesterolemia attenuate the efficacy of lipoprotein apheresis by dextran sulfate adsorption. Drouin-Chartier JP; Tremblay AJ; Bergeron J; Lamarche B; Couture P Atherosclerosis; 2018 Mar; 270():26-32. PubMed ID: 29407885 [TBL] [Abstract][Full Text] [Related]
16. Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France. Bruckert E; Kalmykova O; Bittar R; Carreau V; Béliard S; Saheb S; Rosenbaum D; Bonnefont-Rousselot D; Thomas D; Emery C; Khoshnood B; Carrié A Atherosclerosis; 2017 Feb; 257():130-137. PubMed ID: 28131047 [TBL] [Abstract][Full Text] [Related]
17. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937 [TBL] [Abstract][Full Text] [Related]
18. The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Thompson GR Atheroscler Suppl; 2013 Jan; 14(1):67-70. PubMed ID: 23357143 [TBL] [Abstract][Full Text] [Related]
19. Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry. Luirink IK; Hutten BA; Greber-Platzer S; Kolovou GD; Dann EJ; de Ferranti SD; Taylan C; Bruckert E; Saheb S; Oh J; Driemeyer J; Farnier M; Pape L; Schmitt CP; Novoa FJ; Maeser M; Masana L; Shahrani A; Wiegman A; Groothoff JW Atherosclerosis; 2020 Apr; 299():24-31. PubMed ID: 32199148 [TBL] [Abstract][Full Text] [Related]
20. Managing homozygous familial hypercholesterolaemia from cradle to grave. Thompson GR Atheroscler Suppl; 2015 May; 18():16-20. PubMed ID: 25936299 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]